We are a motivated group of data scientists, clinicians, machine learning experts, and healthcare software developers intensely focused on improving the quality of radiation therapy treatments.

David Lindsay

CEO, Co-Founder

David founded Oncora while pursuing an MD/PhD as part of the Medical Scientist Training Program at the University of Pennsylvania. David’s PhD research centers on automated diagnosis of disease using quantitative medical imaging. David developed clinical knowledge and skills in medical school but also studied regulatory affairs, reimbursement strategy, medical device design, software engineering, and venture capital as part of a series of graduate engineering and business courses. As Oncora’s CEO since founding in 2014, David has developed close relationships with clinical and business leaders in the oncology space and leads partnerships, sales, and investor relations. He is also an active contributor to Oncora’s science and engineering teams, with a particular focus on automated medical image analysis.

Chris Berlind, PhD

CTO, Co-Founder

Chris is a computer scientist and machine learning expert with a PhD from Georgia Tech and BS from Caltech. Chris has nine years of academic and industry research experience and has worked with field-leading experts in both DNA computing and theoretical machine learning. His graduate research, resulting in several publications in top machine learning conferences, focused on theoretically sound algorithms for active learning and on demonstrating that active learning can be used to overcome a variety of obstacles in machine learning. At Oncora, Chris leads product development and research.

Gary Kurtzman, MD

Board Chairman

Gary has 25+ years of experience in operations and investments. He joined Safeguard Scientifics in 2006 where he is responsible for identifying, deploying capital in and supporting emerging healthcare companies in diagnostics, medical devices and healthcare IT. Gary is currently a board member of Good Start Genetics, Medivo, meQuilibrium, Propeller Health, Syapse and Trice Medical and is a board observer at Velano Vascular. He recently realized successful exits with partner companies Advanced BioHealing, Alverix, Avid Radiopharmaceuticals, Crescendo Biosciences and NuPathe to strategic acquirers Shire, Becton Dickinson, Eli Lilly, Myriad, and Teva, respectively. Previously, he was Chief Executive Officer at Pluvita Corporation, a company developing personalized medicine solutions and served as Chief Operating Officer at Genovo, and head of research & development at Avigen, both development stage gene therapy companies. Gary began his career in industry with Gilead Sciences as virology group leader. Gary received his MD degree from Washington University, trained in internal medicine at Barnes Hospital in St. Louis, MO, and completed hematology sub-specialty training at Stanford. 

Chris Ahern, PhD

Data Scientist

Chris has a PhD from the University of Pennsylvania, where his graduate and post-doctoral research focused on applying computational and statistical methods from the fields of evolutionary game theory and population genetics to study language change across large datasets. As a data scientist at Oncora, Chris trains high quality predictive models of clinical events, like tumor recurrence and radiation toxicity.  Ultimately, Chris wants to improve quality of care for cancer patients using past data and intelligent predictive analytics to improve clinical decision making.

Chris Harrill

Software Engineer

Chris Harrill focuses on applying advanced technologies to Oncora's data processing infrastructure. Prior to joining Oncora, Chris gained a diverse set of experiences working in research and software development for a large defense contracting firm, and later worked at a software startup specializing in field service management. Chris joined Oncora seeking to help develop tools with high potential and broad impact that will help improve patients’ lives. He holds a BS in computer engineering from the University of Virginia and is the primary inventor on a patent for web processing service (WPS) workflow.

Angela Holmes

Director of Product and Customer Solutions

With more than 15 years of experience in many industries including healthcare, Angela is an expert in designing and implementing complex software solutions for sophisticated enterprise organizations. Angela is a biomedical engineer with a B.S. from Georgia Tech and M.S. from Johns Hopkins University, and leads product strategy and customer solutions for Oncora. She joined the Oncora team to make precision medicine a reality in cancer care.

Jake Klingler

Software Engineer

Jake is a software engineer with specific expertise in healthcare, UX, and design. While working at Epic, he helped improve one of the largest enterprise electronic medical record systems in the world. At Oncora, he is designing and developing an intuitive software system to help radiation oncologists take better care of cancer patients.

Chris Pasakarnis

Engineering Lead

Chris helps lead the engineering team to build software that helps radiation oncologists deliver better quality of care through advanced predictive analytics. With nearly a decade of experience across the software development and consulting fields, he has most recently helped early and mid stage companies grow their engineering teams and build scalable cloud-based platforms. Chris joined Oncora with the goal of amplifying the team's ability to develop tools that can improve cancer patients' lives.

Alessandra Patrizio

Operations Manager

Alessandra is a graduate of Hobart and William Smith Colleges, where she earned a B.S. in Psychology and competed for their NCAA D-III Field Hockey team. Post college, she worked as a research coordinator for multiple medical laboratories at the University of Pennsylvania. This experience serves her well at Oncora, where in addition to operations, Alessandra helps support clinical and technical research efforts. She is passionate about startups, medical research, and anything that helps improve the lives of cancer patients.